Anthony T Reder Selected Research

Anthony T Reder Research Topics

Disease

33	Multiple Sclerosis 01/2022 - 03/2002
11	Relapsing-Remitting Multiple Sclerosis 01/2022 - 04/2004
6	Infections 01/2021 - 06/2014
3	Injection Site Reaction 01/2021 - 05/2014
3	Disease Progression 01/2021 - 09/2013
3	Neoplasms (Cancer) 01/2021 - 06/2014
3	Bradycardia 09/2014 - 02/2011
3	Macular Edema 07/2013 - 02/2011
2	COVID-19 01/2021 - 01/2021
2	Atrophy 01/2021 - 01/2018
2	Inflammation (Inflammations) 01/2018 - 05/2008
2	Herpes Zoster 01/2015 - 06/2014
2	Atrioventricular Block 09/2014 - 06/2014
2	Demyelinating Diseases (Demyelinating Disease) 12/2011 - 08/2002
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021
1	Thymoma (Thymic Carcinoma) 01/2021
1	Thymus Neoplasms (Thymus Neoplasm) 01/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Temporal Lobe Epilepsy 01/2018
1	Epilepsy (Aura) 01/2018
1	Encephalitis (Encephalitis, Rasmussen) 01/2018
1	Seizures (Absence Seizure) 01/2018
1	Latent Infection 09/2016
1	Respiratory Tract Infections (Respiratory Tract Infection) 09/2016
1	Menstruation Disturbances 01/2016
1	Hypertension (High Blood Pressure) 06/2014
1	Basal Cell Carcinoma (Rodent Ulcer) 06/2014
1	Lymphopenia (Lymphocytopenia) 06/2014
1	Autoimmune Diseases (Autoimmune Disease) 09/2013
1	Uveitis 07/2013
1	Neuromyelitis Optica (Devic's Disease) 02/2012
1	Chronic Disease (Chronic Diseases) 01/2011
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 03/2009
1	Alzheimer Disease (Alzheimer's Disease) 05/2004
1	Central Nervous System Diseases (CNS Diseases) 05/2004
1	Brain Diseases (Brain Disorder) 08/2002

Drug/Important Bio-Agent (IBA)

10	Fingolimod Hydrochloride (FTY720)FDA Link 11/2016 - 02/2011
9	InterferonsIBA 01/2021 - 08/2002
7	Interferon-betaIBA 10/2012 - 08/2002
4	Glatiramer Acetate (Copaxone)FDA Link 06/2021 - 01/2010
4	Neutralizing AntibodiesIBA 01/2021 - 04/2004
3	Interferon beta-1a FDA Link 06/2021 - 01/2021
3	Interferon beta-1b (Betaseron)FDA Link 01/2019 - 04/2004
3	AntibodiesIBA 01/2018 - 06/2004
3	Interferon Type IIBA 08/2014 - 02/2012
2	peginterferon beta-1aIBA 06/2021 - 01/2021
2	Natalizumab (Tysabri)FDA Link 01/2021 - 01/2018
2	GadoliniumIBA 01/2021 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 09/2013 - 10/2010
2	RNA (Ribonucleic Acid)IBA 12/2011 - 05/2008
1	ocrelizumabIBA 01/2022
1	Pharmaceutical PreparationsIBA 06/2021
1	teriflunomideIBA 06/2021
1	diroximel fumarateIBA 01/2021
1	pembrolizumabIBA 01/2021
1	Dimethyl FumarateIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 11/2019
1	Vitamin D FDA LinkGeneric 06/2018
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2018
1	Carboxy-LyasesIBA 01/2018
1	AcidsIBA 01/2018
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2018
1	SteroidsIBA 01/2018
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2018
1	Hormones (Hormone)IBA 01/2016
1	Estriol (Epiestriol)IBA 01/2016
1	Alanine Transaminase (SGPT)IBA 06/2014
1	Transaminases (Aminotransferases)IBA 05/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2012
1	Immunomodulating AgentsIBA 07/2010
1	Immunoglobulins (Immunoglobulin)IBA 01/2010
1	GTP-Binding Proteins (G-Protein)IBA 01/2010
1	4-Aminopyridine (4 Aminopyridine)FDA Link 03/2009
1	Myelin-Oligodendrocyte GlycoproteinIBA 06/2004
1	Apolipoproteins E (ApoE)IBA 05/2004
1	ApolipoproteinsIBA 05/2004
1	CytokinesIBA 08/2002
1	Interleukin-10 (Interleukin 10)IBA 03/2002

Therapy/Procedure

16	Therapeutics 01/2022 - 08/2002
2	Injections 04/2016 - 01/2016
1	Aftercare (After-Treatment) 01/2021
1	Plasma Exchange 01/2018
1	Duration of Therapy 09/2016